Effects of margarines and butter consumption on lipid profiles, inflammation markers and lipid transfer to HDL particles in free-living subjects with the metabolic syndrome

European Journal of Clinical Nutrition

Volumn 64, Issue 10, 2010, Pages 1141-1149

  Gagliardi, A C M ^a   Maranho, R C ^a   Sousa, H P D ^a   Schaefer, E J ^b   Santos, R D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b TUFTS UNIVERSITY   (United States)

Author keywords

butter; HDL; inflammation; margarine; metabolic syndrome; plant sterol

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARGARINE; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID;

ADULT; ARTICLE; BUTTER; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; FEMALE; FOOD COMPOSITION; HUMAN; INFLAMMATION; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; APOLIPOPROTEINS; BIOLOGICAL MARKERS; BUTTER; CARDIOVASCULAR DISEASES; DIETARY FATS; E-SELECTIN; ENDOTHELIUM, VASCULAR; FAT SUBSTITUTES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; LIPOPROTEINS, HDL; MALE; MARGARINE; METABOLIC SYNDROME X; MIDDLE AGED; PHYTOSTEROLS; RISK FACTORS; SINGLE-BLIND METHOD;

EID: 77957826647     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2010.122     Document Type: Article

References (43)

1. Ai M, Otokozawa S, Astalos BF, Nakajima K, Stein E, Jones PH et al. (2008). Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol 101, 315-318.
2. Association of Official Analytical Chemists (AOAC) (2002). Official Methods ofAnalysis., Official Method. n. 996.06, cap 41 AOAC: Arilington., pp 20.
3. Asztalos BF, Schaefer EJ (2003). High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 91, 12E-17E.
4. Calder PC (1998). Fat chance immunomodulation. Immunol Today 19, 244-247.
5. Campos H, Blijlevens E, McNamara JR, Ordovas JM, Posner BM, Wilson PW et al. (1992). LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 12, 1410-1419.
6. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ (1988). Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 29, 469-479.
7. + patients. Rev Inst Med Trop S Paulo 50, 223-227.
8. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R (2005). Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111, 1448-1454.
9. Dayton S, Pearce ML, Goldman H, Harnish A, Plotkin D, Shickman M et al. (1968). Controlled trial of diet high in unsaturated fat for prevention of atherosclerosis complications. Lancet 2, 1060-1062.
10. Demonty I, Ras RT, van der Knaap HCM, Duchateau GSMJ, Meijer L, Zock PL et al. (2009). Continuous dose-response relationship of the LDL cholesterol-lowering effect of plant sterol intake. J Nutr 139, 271-284.
11. Eckel RH, Grundy SM, Zimmet PZ (2005). The metabolic syndrome. Lancet 365, 1415-1428.
12. Gigleux I, Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM et al. (2007). Comparison of a dietary portfolio diet of cholesterol-lowering foods and a statin on LDL particle size phenotype in hypercholesterolaemic participants. Br J Nutr 98, 1229-1236.
13. Giribela AH, Melo NR, Latrilha MC, Baracat EC, Maranhão RC (2009). HDL concentration, lipid transfer to HDL, and HDL size in normolipidemic nonobese menopausal women. Int J Gynecol Obstet 104, 117-120.
14. Grundy SM (2008). Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 28, 629-636.
15. US Department of Health and Human Services, Food and Drug Administration, Center of Drug Evaluation and Research (CDER) and center for Veterinary Medicine (CVM). Guidance for industry-Bioanalytical method validation. Acessed on the wide world web http://www.fda.gov/cder/guidance/index.htm.
16. Han SH, Leka LS, Lichtenstein AH, Ausman LM, Schaefer EJ, Meydani SN (2002). Effect of hydrogenated and saturated, relative to polyunsaturated, fat on immune and inflammatory responses of adults with moderate hypercholesterolemia. J Lipid Res 43, 445-452.
17. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R (2003). Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 78, 965-978.
18. Kontush A, Chapman MJ (2008). Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep 8, 51-59.
19. Kromhout D, Bosschieter EB, De Lezenne Coulander C (1985). The inverse relation fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 312, 1205-1211.
20. Kromhout D, De Lezenne, Coulander C (1984). Diet, prevalence and 10-year mortality from coronary heart disease in 871 middle-aged men. The Zutphen Study. Am J Epidemiol 119, 733-743.
21. Lamarche B, Desroches S, Jenkins DJ, Kendall CW, Marchie A, Faulkner D et al. (2004). Combined effects of a dietary portfolio of plant sterols, vegetable protein, viscous fibre and almonds on LDL particle size. Br J Nutr 2004; 92: 657-663
22. Leren P (1966). The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. Acta Med Scand 466, 1-92.
23. Lewis GF, Rader DJ (2005). New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96, 1221-1232.
24. Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ (1999). Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med 340, 1933-1941.
25. Lichtenstein AH, Erkkila AT, Lamarche B, Schwab US (2003). Influence of hydrogenated fat and butter on CVD risk factors: remnant-like particles, glucose and insulin, blood pressure and C-reactive protein. Atherosclerosis 171, 97-107.
26. Lo Prete AC, Dina CH, Azevedo CH, Puk CG, Lopes NH, Hueb WA et al. (2009). In vitro simultaneous transfer of lipids to hdl in coronary artery disease and in statin treatment. Lipids 44, 917-924.
27. Madsen MB, Jensen AM, Schmidt EB (2007). The effect of a combination of plant sterol-enriched foods in mildly hypercholesterolemic subjects. Clin Nutr 26, 792-798.
28. Maranhão RC, Cesar TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH (1993). Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein. Lipids 28, 691-696.
29. Masson D, Jiang XC, Lagrost L, Tall AR (2009). The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis. J Lipid Res 50, S201-S206.
30. McGee DL, Reed DM, Yano K, Kagan A, Tillotson J (1984). Ten-year incidence of coronary heart disease in the Honolulu Heart Program. Relationship with nutrient intake. Am J Epidemiol 119, 667-677.
31. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J et al. (2008). Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372, 224-233.
32. Miyazaki O, Fukamachi I, Mori A, Hashimoto H, Kawashiri MA, Nohara A et al. (2009). Formation of prebeta 1-HDL during lipolysis of triglyceride-rich lipoprotein. Biochem Biophys Res Commun 379, 55-59.
33. Morton RE (1988). Free cholesterol is a potent regulator of lipid transfer protein function. J Biol Chem 263, 12235-12341.
34. NCEP/III ATP (2002). Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421.
35. Normén L, Frohlich JJ, Trautwein EA (2004). Role of plant sterols in cholesterol lowering. In: Dutta PC (ed). Plant Sterols: Analytical, Nutritional, and Safety Aspects as Functional Food. pp 243-315. New York: Marcel Dekker.
36. Plat J, Brufau G, Dallinga-Thie GM, Dasselaar M, Mensink RP (2009). A plant stanol yogurt drink alone or combined with a low-dose statin lowers serum triacylglycerol and non-HDL cholesterol in metabolic syndrome patients. J Nutr 139, 1143-1149.
37. Puk CG, Bocchi EA, Lo Prete AC, Ferreira SM, Stolf NA, Maranhão RC (2009). Transfer of cholesterol and other lipids from a lipid nanoemulsion to high-density lipoprotein in heart transplant patients. J Heart Lung Transplant 28, 1075-1080.
38. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ (2009). The metabolism and anti-atherogenic properties of HDL. J Lipid Res 50 (Suppl), S195-S200.
39. Schaefer EJ (2002). Lipoproteins, nutrition, and heart disease. Am J Clin Nutr 75, 191-212.
40. Stamler J (1979). Population studies. In: Levy R, Dennis BR, Ernest N (eds). Nutrition, Lipids, and Coronary Heart Disease. pp 25-88. Raven: New York.
41. Trautwein EA, Duchateau GS, Lin YG, Mel'nkiv SM, Molhuizen HOF, Ntanios FY (2003). Proposed mechanism of cholesterol-lowering action of plant sterols. Eur J Lipid Sci Technol 105, 171-185.
42. Turpeinen O (1979). Effect ofcholesterol-lowering diet on mortality from coronary heart disease and other causes. Circulation 59, 1-7.
43. Wang M, Briggs MR (2004). HDL: the metabolism, function, and therapeutic importance. Chem Rev 104, 119-137.